Praluent Cost in New Mexico 2026: Cash Price, Medicaid, Insurance, and Compounded Alirocumab

What Is Alirocumab and Why Does It Matter in New Mexico?

Alirocumab is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors in the liver. Blocking PCSK9 keeps more LDL receptors on the hepatocyte surface, which drives circulating LDL-cholesterol sharply downward. The FDA approved Praluent in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy [1].

New Mexico carries a cardiovascular burden that makes this drug particularly relevant. The CDC reports age-adjusted heart disease death rates across rural and frontier counties in New Mexico that exceed national averages [2]. Familial hypercholesterolemia affects roughly 1 in 250 individuals in the general population, according to the American Heart Association [3]. That translates to an estimated 8,400 to 10,000 New Mexicans living with HeFH, most of them undiagnosed.

The ODYSSEY OUTCOMES trial (N=18,924) tested alirocumab 75-150 mg every two weeks against placebo in patients who had experienced a recent acute coronary syndrome while on high-intensity statin therapy. At a median follow-up of 2.8 years, alirocumab reduced the composite of death from coronary heart disease, non-fatal MI, fatal or non-fatal ischemic stroke, and unstable angina requiring hospitalization by 15% (hazard ratio 0.85; 95% CI 0.78-0.93; P<0.001) [4]. That cardiovascular mortality signal is the clinical foundation behind every prior-authorization fight New Mexico patients face.

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states: "In patients with established ASCVD who require additional LDL-C lowering, a PCSK9 inhibitor is recommended if LDL-C remains above 70 mg/dL on maximally tolerated statin plus ezetimibe therapy" [5]. That guideline language is the lever clinicians use when appealing insurance denials.

Praluent List Price vs. Real Cash Price in New Mexico 2026

The manufacturer list price is $580 per month. That number means almost nothing for most patients.

Regeneron and Sanofi set a wholesale acquisition cost (WAC) that retail pharmacies mark up slightly. Without insurance or a coupon, a New Mexico patient filling at a Walgreens, Walmart Pharmacy, or independent pharmacy in Albuquerque, Santa Fe, or Las Cruces will pay close to that $580 figure. GoodRx and similar platforms offer modest discounts on branded biologics, but the savings on Praluent are typically 5-10% rather than the 70-80% discounts those platforms achieve on generic drugs [6].

Cash pay is the least efficient route for most patients. The savings card program described in the next section is almost always cheaper for commercially insured patients, and compounded alirocumab through a 503A pharmacy is cheaper still for patients who qualify.

One practical note: Praluent comes as a pre-filled pen or syringe in 75 mg/mL and 150 mg/mL concentrations. Patients starting therapy typically begin at 75 mg every two weeks, with uptitration to 150 mg every two weeks if LDL-C response is inadequate at 8-12 weeks [1]. A single pen equals one two-week dose, so a monthly supply requires two pens. The $580 list price reflects both pens.

New Mexico Medicaid Coverage for Praluent

New Mexico Medicaid does not cover Praluent as of mid-2025, and that coverage status has not changed entering 2026. This is a significant access barrier. Medicaid covers approximately 43% of New Mexico's population, one of the highest enrollment ratios in the country [7].

The New Mexico Human Services Department administers Medicaid through managed care organizations including Blue Cross Blue Shield of New Mexico (Turquoise Care), Presbyterian Health Plan, and Molina Healthcare of New Mexico. None of these MCOs list alirocumab on their Medicaid formularies. Evolocumab (Repatha), the competing PCSK9 inhibitor from Amgen, shares the same coverage exclusion.

Patients enrolled in New Mexico Medicaid who need PCSK9 inhibition have three practical paths. First, they can apply for the Regeneron/Sanofi Patient Assistance Program (PAP), which provides Praluent at no cost to uninsured or underinsured patients meeting income criteria (generally below 400% of the federal poverty level) [8]. Second, they can enroll in a clinical trial studying PCSK9 inhibitors. Third, they can explore compounded alirocumab, discussed below.

Physicians writing for Medicaid patients should document statin intolerance, maximally tolerated statin use, and LDL-C values in the medical record in detail. That documentation supports PAP applications and any future formulary exception requests if coverage policy changes [5].

Commercial Insurance Prior Authorization in New Mexico

Every major commercial insurer operating in New Mexico, including Presbyterian Health Plan commercial lines, Blue Cross Blue Shield of New Mexico, Cigna, Aetna, and UnitedHealthcare, requires prior authorization for Praluent. Step therapy is standard. Insurers typically require documentation of all three of the following before approving:

1. A diagnosis of HeFH (confirmed by genetic testing or Dutch Lipid Clinic Network score) or established ASCVD.
2. A trial of at least one high-intensity statin, usually atorvastatin 40-80 mg or rosuvastatin 20-40 mg, at maximally tolerated doses.
3. An LDL-C that remains above a threshold (usually 70 mg/dL for ASCVD or 100 mg/dL for FH) despite statin plus ezetimibe.

The ACC/AHA recommends that clinicians "initiate PCSK9 inhibitor therapy rather than stopping statin therapy" when a patient is statin intolerant and LDL-C remains above goal [5]. That sentence from a named guideline belongs in every PA letter.

Denial rates for PCSK9 inhibitors remain high nationally. A 2019 analysis in the Journal of the American College of Cardiology found that 54% of initial PCSK9 inhibitor PA requests were denied, and 28% of appeals were also denied [9]. New Mexico prescribers should expect to write at least one appeal letter. The appeal should cite ODYSSEY OUTCOMES hazard ratio data, patient-specific LDL-C values, and the 2022 ACC/AHA guideline text directly.

If a commercial plan approves Praluent, the Regeneron/Sanofi savings card reduces patient cost-sharing to $0 per month for eligible commercially insured patients, subject to a maximum annual benefit. Patients enroll at praluent.com or through the prescribing clinician's office. The savings card does not apply to Medicare Part D, Medicaid, or any government-funded plan.

How the Regeneron/Sanofi Savings Card Works in New Mexico

The savings card functions as a copay offset. After commercial insurance pays its contracted rate, the savings card covers the remaining patient cost-sharing up to the program's per-fill cap. In 2026, Regeneron/Sanofi has maintained a $0 copay offer for eligible commercially insured patients, meaning most patients with approved coverage pay nothing out of pocket at the pharmacy [8].

Eligibility rules are specific. The patient must have commercial insurance (not Medicare, Medicaid, or any federal or state government plan). The patient must be a US resident. The prescription must be for an FDA-approved indication. Patients with Medicare Part D cannot use the savings card due to federal anti-kickback statute restrictions; they should ask about the Regeneron Patient Assistance Program instead [8].

To activate the card in New Mexico: the prescribing physician sends a prior authorization request, approval is obtained, the prescription is sent electronically to the patient's preferred pharmacy, and the patient presents the savings card (physical or digital) at pickup. The process takes one to three weeks from prescription to first injection.

For patients denied commercial insurance coverage, the out-of-pocket cost without the card reverts to the approximately $580 list price. In that scenario, the Regeneron PAP or compounded alirocumab becomes the next step.

Compounded Alirocumab in New Mexico: Legality and Availability

Compounded alirocumab is available in New Mexico through licensed 503A compounding pharmacies. This is a state-specific fact that matters enormously for cost.

Under federal law, Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare drug compounds for individual patients based on a valid prescription from a licensed practitioner [10]. Alirocumab is not on the FDA's list of drugs that may not be compounded under 503A as of mid-2025. New Mexico's Board of Pharmacy licenses 503A compounding pharmacies and permits compounding of complex biologics for patient-specific prescriptions [11].

The practical implication: a New Mexico physician or telehealth prescriber licensed in New Mexico can write a patient-specific prescription for compounded alirocumab, and a licensed 503A pharmacy (in-state or out-of-state, provided the pharmacy holds the appropriate state license) can fill it. Compounded versions of PCSK9 inhibitors are marketed at costs substantially below the Praluent list price, with some pharmacies offering $0/month introductory pricing through HealthRX partner networks.

Critical caveats apply. Compounded drugs are not FDA-approved. The FDA has not evaluated compounded alirocumab for safety, efficacy, or sterility at the batch level. The American College of Cardiology notes that "the clinical evidence base for PCSK9 inhibitors is specific to the branded, FDA-approved formulations studied in large randomized controlled trials" [5]. Patients choosing compounded alirocumab should understand they are using a preparation that has not undergone the same regulatory review as Praluent and should work with a clinician who will monitor LDL-C response at 8-12 weeks to confirm efficacy [4].

The legality question has a direct answer: compounded alirocumab prescribed for an individual patient by a licensed New Mexico practitioner and dispensed by a licensed 503A pharmacy is legal under current federal and New Mexico state law. It is not legal to purchase compounded alirocumab without a valid prescription, and 503B outsourcing facilities may not compound alirocumab unless it appears on the FDA's drug shortage list [10].

Telehealth Prescribing of Praluent in New Mexico

Telehealth prescribing of Praluent is legal and fully operational in New Mexico. The state follows the Interstate Medical Licensure Compact, allowing physicians licensed in compact member states to practice telemedicine across state lines with a compact license [12]. New Mexico also permits advanced practice registered nurses and physician assistants to prescribe Schedule II-V controlled substances and non-controlled medications via telehealth under appropriate collaborative agreements.

For PCSK9 inhibitors specifically, a telehealth visit can establish or confirm the indication (HeFH or ASCVD), review prior lipid panels and statin history, generate the prior authorization documentation, and send the prescription electronically to a New Mexico pharmacy or to a mail-order pharmacy licensed in New Mexico. Labs must be reviewed; a lipid panel drawn within the past 12 months is typically sufficient for the initial PA request, though insurers may require a panel drawn while on maximally tolerated statin therapy.

HealthRX providers licensed in New Mexico can conduct the full prescribing and PA process remotely. Patients typically need one initial visit (30-45 minutes) and a follow-up at 8-12 weeks to assess LDL-C response [4].

Clinical Dosing and Monitoring for New Mexico Prescribers

Alirocumab dosing follows the FDA label precisely. The starting dose is 75 mg subcutaneously every two weeks. If LDL-C response is inadequate after 8-12 weeks of therapy, the dose increases to 150 mg every two weeks [1]. A flat monthly dosing option of 300 mg once monthly is also approved for patients who prefer less frequent injections [1].

LDL-C reductions are dose-dependent. In ODYSSEY LONG TERM (N=2,341), alirocumab 150 mg every two weeks reduced LDL-C by a mean of 61% from baseline at 24 weeks compared to placebo (P<0.001) [13]. The 75 mg every two weeks starting dose produces roughly 45-50% LDL-C reduction in most patients [14].

Injection technique matters for adherence. Patients should rotate injection sites among the abdomen, upper arm, and thigh. The pre-filled pen should reach room temperature for at least 30-40 minutes before injection. Cold injections from the refrigerator increase local pain and may reduce patient willingness to continue therapy. The prescribing clinician or a nurse should demonstrate injection technique at the first encounter, even in a telehealth context (using video demonstration).

Monitoring requirements are minimal compared to most cardiovascular medications. A fasting lipid panel at 8-12 weeks after starting or dose-adjusting confirms response [5]. Liver function testing is not routinely required. Injection site reactions occur in approximately 7% of patients in clinical trials but are rarely severe enough to discontinue therapy [1].

Choosing Between Alirocumab and Evolocumab in New Mexico

Evolocumab (Repatha, Amgen) is the only other approved PCSK9 inhibitor in the United States. The two drugs share the same mechanism, similar LDL-C efficacy, and near-identical formulary positions across New Mexico commercial plans. Neither is covered by New Mexico Medicaid.

The practical differences are small. Evolocumab has a cardiovascular outcomes trial (FOURIER, N=27,564) demonstrating a 15% reduction in the primary composite endpoint at 2.2 years median follow-up [15]. Alirocumab has ODYSSEY OUTCOMES. Both trials used similar patient populations and reached comparable hazard ratios. Neither drug has demonstrated superiority over the other in a head-to-head trial.

Cost differences at list price are minor. Amgen's Repatha list price is similarly approximately $580-620 per month in 2026. Both manufacturers offer comparable patient assistance programs. Insurance formulary tier placement varies by plan; occasionally one insurer will place evolocumab on a preferred tier versus alirocumab or vice versa, so it is worth checking the specific formulary before prescribing.

A practical rule: check the patient's insurance formulary first. If one PCSK9 inhibitor is preferred, prescribe that one. If both are non-preferred or excluded, the clinical choice between them is largely interchangeable, and the patient-assistance program access and compounding availability become the deciding factors.

Step-by-Step Access Plan for New Mexico Patients in 2026

The following decision sequence applies to most New Mexico patients seeking alirocumab in 2026:

Step 1. Confirm the indication. Document HeFH (Dutch Lipid Clinic Network score of 6 or above, or positive genetic test) or established ASCVD (prior MI, stroke, or symptomatic peripheral arterial disease) in the chart [5].

Step 2. Document maximally tolerated statin therapy. Record the statin name, dose, and duration. If statin intolerant, document each trial and the specific adverse effect. Ezetimibe use should also be documented [5].

Step 3. Obtain a current lipid panel. A fasting LDL-C above 70 mg/dL (ASCVD) or 100 mg/dL (FH) on documented therapy satisfies most PA criteria [5].

Step 4. Submit the PA. Include the ODYSSEY OUTCOMES HR 0.85 data [4], the current guideline recommendation text [5], and the patient's specific LDL-C history. Expect a 5-15 business-day turnaround from New Mexico commercial insurers.

Step 5. If denied, appeal immediately. Use the same clinical data. Request a peer-to-peer review. Most commercial insurers approve at peer-to-peer review when clinical criteria are clearly met.

Step 6. Activate the savings card. Once approved, enroll the patient at the manufacturer's website. The $0 copay applies at point of sale for eligible commercially insured patients [8].

Step 7. If coverage is not obtainable. Apply for the Regeneron PAP (income-based, no-cost drug) or discuss compounded alirocumab through a licensed New Mexico 503A pharmacy with appropriate informed consent regarding the non-FDA-approved status.

Step 8. Monitor. Recheck fasting lipid panel at 8-12 weeks. If LDL-C response is inadequate on 75 mg every two weeks, uptitrate to 150 mg every two weeks [1].